Table 2.
Factors associated with acid-related findings among 1569 men and women undergoing esophagogastroduodenoscopy (EGD).
| Characteristic | Total N | Acid-related finding N (%) |
p-value |
|---|---|---|---|
| N | 1569 | 690 (44.0) | |
| Gender | |||
| Male | 882 | 456 (51.7) | <.0001 |
| Female | 685 | 233 (34.0) | |
| Age | |||
| < 50 | 362 | 140 (38.7) | .04 |
| 50 – 59 | 414 | 176 (42.5) | |
| 60 – 69 | 433 | 200 (46.2) | |
| ≥ 70 | 356 | 173 (48.6) | |
| Race/Ethnicity | |||
| White | 1299 | 586 (45.1) | .18 (MC) |
| Black | 85 | 26 (30.6) | |
| Asian/Pacific Islander | 9 | 4 (44.4) | |
| American Indian/Alaskan Native | 40 | 17 (42.5) | |
| Multi-racial | 33 | 11 (33.3) | |
| Hispanic (any race) | 87 | 40 (46.0) | |
| Other | |||
| Body Mass Index (kg/m2) Categories |
|||
| < 25 | 483 | 196 (40.6) | .12 |
| 25 to < 30 | 545 | 256 (47.0) | |
| ≥30 | 531 | 234 (44.1) | |
| Self-reported medical history | |||
| Diabetes | 256 | 117 (45.7) | .54 |
| Acid-reflux | 1094 | 510 (46.6) | .00 |
| Heartburn | 447 | 205 (45.9) | .36 |
| Previous upper GI disease* | 702 | 354 (50.4) | <.0001 |
| Any PPI† use | 865 | 376 (43.5) | .65 |
| H2 Blocker‡ use | 137 | 65 (47.5) | .39 |
| NSAID§ use | 235 | 113 (48.1) | .17 |
MC, computed using Monte Carlo estimate due to small cell sizes
*
Previous upper GI disease includes any one of the following: Gastroparesis, Peptic Ulcer disease, Gastritis, Esophagitis
†
PPI use includes any of the following: Lansoprazole, Omeprazole, Rabeprazole, Pantoprozole, Esomeprazole
‡
H2 Blocker use includes any of the following: Famotidine, Nizatidine, Ranitidine, Cimetidine
§
NSAID use includes prescription and over the counter